Form 4 for MGX Metagenomi Therapeutics, Inc.
Accepted 2025-04-03 00:00:00 ET · period of report 2025-04-01 · accession 0000950170-25-050098 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-04-03 | 2025-04-01 | MGX | Noonberg Sarah B. | Chief Medical Off | A - Grant | $0.00 | +14.0K | 114.4K | +14% | $0 |
| D | 2025-04-03 | 2025-04-01 | MGX | Noonberg Sarah B. | Chief Medical Off | A - Grant | $0.00 | +84.0K | 84.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-01 | A | A | 14,000 | $0.00 | 114,374 | D | — | — | (F1) These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2026, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-04-01 | A | A | 84,000 | $0.00 | 84,000 | D | $1.32 · — to 2035-03-31 | 84,000 Common Stock | (F2) 25% of the shares subject to this option shall vest and become exercisable on April 1, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. |